Antibodies, Monoclonal (toxicity) < Antibodies, Monoclonal, Humanized < Antibodies, Monoclonal, Humanized (administration & dosage)

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by Antibodies, Monoclonal, Humanized

Number of relevant bibliographic references: 322.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000012 (2020)	Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis]	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety.
000149 (2020)	Emre Bilgin [Oman] ; Rem Ozarli [Turquie] ; Levent K L Ç [Turquie] ; Ertu Rul Ça R Bölek [Turquie] ; Gözde Kübra Yard Mc [Turquie] ; Ömer Karada [Turquie]	Some concerns from Turkey.
000190 (2020)	Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]	Response to: 'Some concerns from Turkey' by Bilgin et al.
000245 (2020)	Ana Luisa Oliveira [Portugal] ; Carina Ruano [Portugal] ; Nuno Riso [Portugal] ; José Cepeda Ribeiro [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]	Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia.
000351 (2020)	Etienne Dufranc [France] ; Arnaud Del Bello [France] ; Julie Belliere [France] ; Nassim Kamar [France] ; Stanislas Faguer [France]	IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
000437 (2020)	Catalina Sanchez-Alvarez [États-Unis] ; Matthew Koster [États-Unis] ; Ali Duarte-García [États-Unis] ; Kenneth J. Warrington [États-Unis]	Disease progression of Takayasu arteritis in two patients treated with tocilizumab.
000582 (2020)	Franco Maria Buonaguro [Italie] ; Igor Puzanov [États-Unis] ; Paolo Antonio Ascierto [Italie]	Anti-IL6R role in treatment of COVID-19-related ARDS
000708 (2019)	Young Ho Lee [Corée du Sud]	Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment.
000894 (2019)	Emma L. Simpson [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma S. Hock [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Rachel Archer [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Matthew D. Stevenson [Royaume-Uni] ; Chloé Herpin [France] ; Salah Ghabri [France]	Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
000905 (2019)	Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]	Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee.
000906 (2019)	Yoshikazu Nakaoka	Response to: 'Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis' by Lee and Song.
000907 (2019)	Dinesh Khanna [États-Unis] ; Angelika Jahreis [États-Unis] ; Celia J F. Lin [États-Unis]	Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.
000908 (2019)	Yoshikazu Nakaoka [Japon]	Response to: 'Aortic ulceration in a tocilizumab-treated patient with Takayasu arteritis' by Liebling et al.
000954 (2019)	Diederik De Cock [Belgique] ; Patrick Verschueren [Belgique]	Primus inter pares: the choice of biologic drugs in rheumatoid arthritis.
000B53 (2019)	Diego Strianese [Arabie saoudite] ; Francesca Rossi [Italie]	Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.
000D19 (2019)	Young Ho Lee [Corée du Sud] ; Gwan Gyu Song [Corée du Sud]	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis.
000D35 (2019)	Javier Narváez [Autriche] ; Judit Lluch [Espagne] ; Juan José Alegre Sancho [Espagne] ; Maria Molina-Molina [Espagne] ; Joan Miquel Nolla [Espagne] ; Ivan Castellví [Espagne]	Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series.
000E52 (2019)	Thomas Frisell [Suède] ; Johan Askling [Suède]	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.
000E53 (2019)	Thomas Frisell [Suède] ; Johan Askling [Suède]	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply.
000E54 (2019)	Hasan Sat ; Gülce Ecem Can [Turquie] ; Reyhan Bilici Salman ; Asl Han Avano Lu Güler ; Hazan Karadeniz ; Abdurrahman Tufan	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.
000E55 (2019)	Andrew N B. Weil [Royaume-Uni]	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from a nationwide Swedish register.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antibodies, Monoclonal, Humanized" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antibodies, Monoclonal, Humanized" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antibodies, Monoclonal, Humanized
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021